{"id":125080,"date":"2026-09-03T10:26:17","date_gmt":"2026-09-03T10:26:17","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/125080\/"},"modified":"2026-09-03T10:26:17","modified_gmt":"2026-09-03T10:26:17","slug":"koreas-alteogen-inks-3-2-b-deal-with-novartis-for-development-of-hybrozyme-enabled-subcutaneous-products","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/125080\/","title":{"rendered":"Korea&#8217;s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme\u2122-enabled subcutaneous products"},"content":{"rendered":"<p>\t\t\t\t\t\tKorea&#8217;s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme\u2122-enabled subcutaneous products<\/p>\n<p class=\"float-left\">September 3, 2026 | Thursday | News<\/p>\n<p>\t\t\t\t\t\t\tNovartis obtains rights to develop and commercialise subcutaneous formulations for multiple products utilising ALT-B4&#13;<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/screenshot_3_9_2026_145725_alteogen_com-28312.jpeg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"\"\/><\/p>\n<p style=\"text-align: justify;\">South Korea based Alteogen Inc. has entered into an option and license agreement with Novartis for the development and commercialisation of subcutaneous (SC) products utilising ALT-B4 powered by Alteogen&#8217;s Hybrozyme\u2122\u00a0technology.<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">Under the terms of the agreement, Novartis will have multiple options to obtain exclusive rights to develop and commercialize subcutaneous formulations for multiple Novartis products using Alteogen&#8217;s ALT-B4 (berahyaluronidase alfa).<\/p>\n<p style=\"text-align: justify;\">ALT-B4 (berahyaluronidase alfa) is a proprietary recombinant human hyaluronidase developed using Alteogen&#8217;s Hybrozyme\u2122\u00a0platform technology. ALT-B4 enables the conversion of biologics typically administered via intravenous (IV) infusion into more convenient and rapid subcutaneous (SC) formulations. By temporarily depolymerizing hyaluronan in the extracellular matrix, ALT-B4 facilitates the rapid and efficient dispersion and absorption of co-administered therapeutics. The agreement demonstrates Novartis&#8217; commitment to innovating new options for patients and enhancing the treatment experience. \u00a0<\/p>\n<p class=\"prntal\" style=\"text-align: justify;\">If all options are exercised and all milestones are achieved, Alteogen would be eligible to receive up to $3,223 million, including option exercise fees, development and commercial milestone payments, as well as royalties on net sales of products commercialised under the agreement.<\/p>\n","protected":false},"excerpt":{"rendered":"Korea&#8217;s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme\u2122-enabled subcutaneous products September 3, 2026 |&hellip;\n","protected":false},"author":2,"featured_media":125081,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[60731,8330,60733,206,1220],"class_list":["post-125080","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-alteogen","tag-big-pharma","tag-hybrozyme","tag-novartis","tag-south-korea"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117206632989979938","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=125080"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125080\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/125081"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=125080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=125080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=125080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}